Company: NUTR
Filing Date: 2025-03-25
Form Type: CORRESP
Source: 0001641172-25-000449
Chunk: 62

Company: NUSATRIP Inc
Filing Date: 2025-03-25
Form: CORRESP
Chunk 62
---
 to fund all of the proposed purposes, we will decrease our allocation of the net proceeds for the purposes set out above on
a pro rata basis. We would anticipate raising additional capital through equity or debt financing sufficient to fund our proposed uses
above.

The amounts and timing of any expenditures will vary
depending on the amount of cash generated by our operations, and the rate of growth, if any, of our business, and our plans and business
conditions. The foregoing represents our current intentions based upon our present plans and business conditions to use and allocate the
net proceeds of the IPO. Our management will have significant flexibility in applying and discretion to apply the net proceeds of the
IPO. If an unforeseen event occurs or business conditions change, we may use the proceeds of the IPO differently than as described in
this prospectus.

Pending deployment of the net proceeds for the uses
described above, the funds may be placed in short-term deposits with financial institutions or used to invest in short-term money market
instruments.

We will not receive any proceeds from the sales of
shares of our Common Stock by the Selling Stockholders.

<div align='center'>DIVIDEND POLICY</div>

We have no formal dividend policy. We have never declared
or paid cash dividends on our Common Stock. We intend to retain all available funds and any future earnings, if any, to fund our business
and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will
be made at the discretion of our Board of Directors and will depend upon our results of operations, financial condition, contractual restrictions,
indebtedness, restrictions imposed by applicable law and other factors our Board of Directors deems relevant.

| 37 |

<div align='center'>CAPITALIZATION</div>

The following tables set forth our capitalization
as of September 30December 31, 2024:

● on an actual basis; and

● on a pro forma as basis to reflect the issuance
and sale of 2,7003,000,000 shares of Common Stock at an assumed initial public offering price of $4.5 per share
after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

● on a pro forma as adjusted basis to reflect
(i) the issuance and sale of 2,7003,000,000 shares of Common Stock at an assumed initial public offering price
of $4.5 per share after deducting the underwriting discounts and